Related Experiment Video
Updated: Aug 29, 2026

Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders
Published on: August 18, 2016
Increased plasma levels of thioredoxin in patients with coronary spastic angina
Insights
Plasma thioredoxin levels are significantly higher in patients with coronary artery spasm, indicating it is a risk factor. Increased thioredoxin is linked to more frequent angina attacks, suggesting a role in disease activity.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Background:
- Coronary artery spasm, a condition causing chest pain, requires better diagnostic markers.
- Thioredoxin is a protein with known roles in oxidative stress and inflammation.
Purpose of the Study:
- To investigate the association between plasma thioredoxin levels and coronary artery spasm.
- To identify thioredoxin as a potential biomarker for coronary artery spasm.
Main Methods:
- Plasma thioredoxin levels were measured in 170 patients undergoing coronary arteriography.
- Patients were categorized into coronary spastic angina (n=84) and chest pain syndrome (n=86) groups.
- Statistical analyses, including multiple logistic regression, were performed.
Main Results:
- Plasma thioredoxin levels were significantly higher in the coronary spastic angina group compared to the chest pain syndrome group (40.7 ± 4.1 vs. 18.2 ± 1.1 ng/ml, p<0.0001).
- Elevated thioredoxin levels correlated with increased angina attack frequency (p=0.0004).
- Higher plasma thioredoxin (RR 14.8) and current smoking (RR 3.39) were independent risk factors for coronary spasm.
Conclusions:
- Plasma thioredoxin levels are elevated in patients with coronary artery spasm.
- Thioredoxin may serve as a valuable biomarker for diagnosing and assessing the activity of coronary artery spasm.
- Both plasma thioredoxin and smoking are independent risk factors for coronary artery spasm.
Abstract:
To determine whether plasma levels of thioredoxin are associated with coronary spasm, we measured the plasma levels of thioredoxin in 170 patients who had <25% organic stenosis in coronary arteriography. According to the results of cardiac catheterization, we divided the patients into two groups: a coronary spastic angina group (n=84) and a chest pain syndrome group (n=86). The plasma levels of thioredoxin were significantly higher in the coronary spastic angina group than in the chest pain syndrome group (40.7 +/- 4.1 versus 18.2 +/- 1.1 ng/ml, p<0.0001). Furthermore, the increased plasma levels of thioredoxin were associated with high disease activity indicated by the frequency of angina attacks (p=0.0004). In multiple logistic regression analysis, the higher levels of thioredoxin [relative risk 14.8, 95% confidence interval (5.13-42.9), p<0.0001] and current smoking [relative risk 3.39, 95% confidence interval (1.31-8.75), p=0.012] were significant and independent variables associated with coronary spasm. We demonstrated that the plasma levels of thioredoxin were increased in the coronary spastic angina group, and increased levels of thioredoxin were associated with high disease activity. The plasma levels of thioredoxin and current smoking were risk factors for coronary spastic angina, and they were independent from other traditional risk factors.
Related Concept Videos
Angina III: Clinical Manifestations and Assessment
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease V: Interprofessional Care
Angina II: Classification
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Angina I: Introduction

